SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after Fridays selloff has turned the discussion from Black Monday crash warnings to whether the market can sustain the bounce. Traders debate whether it reflects genuine dip-buying or a fragile overnight short-covering move, with some linking optimism to possible Russia-Ukraine developments and easing oil prices while others expect a reversal.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The prolonged wait for SELLASs REGAL Phase 3 trial to reach its 80th death eventand the subsequent final analysisdominates discussion; the last disclosed count was 78, and the company has not confirmed the trigger. Bulls interpret the delay and quiet period as a possible sign of longer survival and speculate about an ASH data reveal, while skeptics see uncertainty around the trial and disclosure timeline; the stocks sharp decline has intensified that debate.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech- and AI-led selloff has put QQQ under pressure, while a strong rebound in futures prompted traders to debate whether the bounce can hold or is a bull trap. Black Monday anniversary crash warnings amplified the volatility, but many traders dismissed them as the rebound gathered momentum.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under pressure amid IPO lockup expirations that make additional insider and employee shares eligible for sale, compounded by a broader AI and semiconductor selloff. Traders disagree on whether the added supply and concerns about valuation, scalability, and customer concentration will prolong the decline or whether the selloff is overdone given Cerebras inference technology.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor selloff, with its 3 leverage magnifying losses and the subsequent rebound. Traders are split between buying an oversold bounce and expecting more downside amid concerns about AI spending and debt, Chinese competition, and persistent inflation.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad neocloud and AI-infrastructure selloff as investors question the sectors debt-fueled expansion, financing costs, and path to returns. Traders are split between viewing the decline as an overdone pullbackoften arguing Nebius is better positioned than some peersand expecting further downside amid sector-wide risk concerns.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is drawing attention after a sharp price and volume rally, with traders watching for a sustained technical breakout. Bullish holders point to the Flexa/Anvil payments and collateral thesis, while skeptics argue the move may be another short-lived pump; no confirmed new catalyst dominates the discussion.

Direxion Shares ETF Trust - Direxion Daily MU Bull 2X ETF

Direxion Daily MU Bull 2X Shares

MUU is drawing attention amid a sharp pullback in Micron and memory stocks, with traders debating whether sector selling and concerns about AI demand signal further downside or a buying opportunity. Some are adding for a rebound, while others warn that MUUs 2x leverage can amplify losses and volatility decay during choppy trading.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO updates on Iovances lifileucel program are driving attention, especially mature frontline melanoma data for lifileucel plus pembrolizumab that traders view as showing durable activity. The reaction is mixed: some see the results as supportive of the ongoing Phase 3 trial, while others argue the small cohort and largely consistent readout limit how much is new; early sarcoma results are also being watched cautiously pending larger-trial validation.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

A strong quarterly report and upbeat cloud outlook drove a sharp rally, with traders also discussing Atlassians AI products as evidence that enterprise software can benefit from rather than be displaced by AI. Some see cloud demand and improving execution supporting the recovery, while others warn the run-up is overextended and point to valuation and AI-related seat-compression risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Options Traders Betting on a Big Move in Sierra Bancorp Stock?

Investors need to pay close attention to BSRR stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Sierra Bancorp Stock?

Compared to Estimates, Sierra Bancorp (BSRR) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Sierra Bancorp (BSRR) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Sierra Bancorp (BSRR) Lags Q2 Earnings and Revenue Estimates

Sierra Bancorp (BSRR) delivered earnings and revenue surprises of -13.48% and -0.81%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Sierra Bancorp Reports Financial Results for Second Quarter and First Six Months of 2026

Sierra Bancorp (Nasdaq: BSRR), parent of Bank of the Sierra, today announced its unaudited financial results for the three- and six-month periods ended June 30, 2026. Sierra Bancorp reported consolidated net income of $9.9 million, or $0.77 per diluted share, for the second quarter of 2026...

Sierra Bancorp Announces 4% Increase in Quarterly Cash Dividend

Sierra Bancorp (Nasdaq: BSRR), parent of Bank of the Sierra, announced that its Board of Directors has declared a regular quarterly cash dividend of $0.27 per share. This represents an increase of $0.01 per share, or 4%, relative to the dividend paid last quarter. The dividend was approved...

Cathay General (CATY) Q2 Earnings and Revenues Surpass Estimates

Cathay (CATY) delivered earnings and revenue surprises of +3.01% and +1.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Sierra Bancorp Stock Options

Investors need to pay close attention to BSRR stock based on the movements in the options market lately. 

Sierra Bancorp's (BSRR) "Buy" Rating Reiterated at DA Davidson

DA Davidson reissued a "buy" rating and issued a $44.00 target price on shares of Sierra Bancorp in a report on Tuesday...

Sierra Bancorp (BSRR) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Sierra Bancorp (BSRR) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Sierra Bancorp is a holding company, which engages in the business of holding the stock of the Bank of the Sierra and its subsidiaries. The firm is also involved in the provision of specialized lending services through a dedicated agricultural credit office. Its loan portfolio includes agricultural, commercial, consumer, real estate, construction, and mortgage. The company was founded by James C. Holly in 1978 and is headquartered in Porterville, CA.

Sierra Bancorp

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$39.59
Prev Close	$39.15
Open	$39.25
Dividend Yield	3.06%
50-Day Moving Average	$39.98
Beta	0.85
Avg. Volume	46,963.00
PE Ratio	11.60

52-Week High	$43.13
52-Week Low	$26.49
Market Capitalization	$513.22M
EPS (Annual)	$3.11
Price to Book	1.40
Revenue Per Employee	$430,750.53

Feed

News

Sentiment

Earnings

Fundamentals

Info

BSRR Fundamentals